Comparison
Argireline vs. BPC-157
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Healing
CAS no.
616204-22-9
137525-51-0
Molecular weight
888.99 g/mol
1419.5 g/mol
Half-life
no data
4 h
Sequence
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2GEPPPGKPADDAGLVMechanism of action
Argireline
Argireline is a synthetic hexapeptide whose sequence corresponds to the N-terminus of the SNAP-25 protein. In vitro it has been shown to competitively inhibit SNARE complex formation (necessary for vesicle fusion in neurotransmitter release). Topical application is intended — given very limited skin permeation — to attenuate cholinergic signalling at the neuromuscular endplate. The effect is orders of magnitude weaker than intramuscular botulinum toxin; the clinical translatability of the in-vitro observations to the skin microenvironment is contested.
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
Evidence base
Highest evidence
Human trial
Animal model
Studies
3
4
of which in humans
2
0
Effects recorded
3
4
Open conflicts
1
2
Documented adverse events
1
2